To determine the material aspects to include in our reporting, we reached out to stakeholders such as patient associations, investors and employees. In addition, we reviewed topics referred to in the Dow Jones Sustainability Indices and in other biotech and pharmaceutical companies’ reporting, or identified by industry associations. Internally, materiality workshops were conducted with representatives from virtually every area of our company, followed by one-on-one interviews with Actelion experts. In addition, a wide variety of company literature and research was reviewed.

Based on this process, the issues deemed most material to Actelion and to our stakeholders are shown on the next page.